ArticleDrugs in R&D2018

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

Sebastiano Buti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.